Drug lookup | Fillwise

Accel-Leflunomide · DIN 02478862 · 10mg · tablet

General benefitMarketed · checked 2026-09-19

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Accel-Leflunomide · DIN 02478862 Manufacturer: Accel Pharma Inc.; listing date 2019-12-20 Health Canada: Marketed since 2019-09-19 · brand ACCEL-LEFLUNOMIDE · ATC L04AK01 LEFLUNOMIDE · form Tablet · route Oral · ingredients LEFLUNOMIDE 10 MG · company Accel pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

Accel-Leflunomide: Formulary list price $2.0000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96957 · Verify on the e-Formulary ↗ (DIN 02478862)

Source record

DIN 02478862: Accel-Leflunomide Raw flags: sec3=Y Item: 920000369; group id 926; item number 2205; lccId None; manufacturer id ACC Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $2.0000; ministry $2.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02478862 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96957

Interchangeable products

Apo-Leflunomide · DIN 02256495 · $2.0000 Arava · DIN 02241888 · $2.0000 Leflunomide · DIN 02351668 · $2.0000 Leflunomide · DIN 02543575 · $2.0000 Mar-Leflunomide · DIN 02551918 · $2.0000 Sandoz Leflunomide · DIN 02283964 · $2.0000 Teva-Leflunomide · DIN 02261251 · $2.0000

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02478862

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Leflunomide · DIN 02256495 · 10mg · tablet

General benefitMarketed · checked 2026-09-19

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Apo-Leflunomide · DIN 02256495 Manufacturer: Apotex Inc.; listing date 2004-11-16 Health Canada: Marketed since 2004-09-14 · brand APO-LEFLUNOMIDE · ATC L04AK01 LEFLUNOMIDE · form Tablet · route Oral · ingredients LEFLUNOMIDE 10 MG · company Apotex inc · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $2.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74173 · Verify on the e-Formulary ↗ (DIN 02256495)

Source record

DIN 02256495: Apo-Leflunomide Raw flags: sec3=Y Item: 920000369; group id 926; item number 2205; lccId None; manufacturer id APX Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $2.6433; ministry $2.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02256495 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74173

Interchangeable products

Accel-Leflunomide · DIN 02478862 · $2.0000 Arava · DIN 02241888 · $2.0000 Leflunomide · DIN 02351668 · $2.0000 Leflunomide · DIN 02543575 · $2.0000 Mar-Leflunomide · DIN 02551918 · $2.0000 Sandoz Leflunomide · DIN 02283964 · $2.0000 Teva-Leflunomide · DIN 02261251 · $2.0000

Shortage status: shortage reported ended 2026-08-13 (report last updated 2026-08-13); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02256495

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Arava · DIN 02241888 · 10mg · tablet

General benefitMarketed · checked 2026-09-19

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Savings card: RxHelp ONE lists Arava (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)

1 brand, same coverage

Arava · DIN 02241888 Manufacturer: Sanofi Aventis Pharma; listing date 2001-03-07 Health Canada: Marketed since 2008-11-03 · brand ARAVA · ATC L04AK01 LEFLUNOMIDE · form Tablet · route Oral · ingredients LEFLUNOMIDE 10 MG · company Sanofi-aventis canada inc · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $2.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65558 · Verify on the e-Formulary ↗ (DIN 02241888)

Source record

DIN 02241888: Arava Raw flags: sec3=Y Item: 920000369; group id 926; item number 2205; lccId None; manufacturer id SAV Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $11.4440; ministry $2.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02241888 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65558

Interchangeable products

Accel-Leflunomide · DIN 02478862 · $2.0000 Apo-Leflunomide · DIN 02256495 · $2.0000 Leflunomide · DIN 02351668 · $2.0000 Leflunomide · DIN 02543575 · $2.0000 Mar-Leflunomide · DIN 02551918 · $2.0000 Sandoz Leflunomide · DIN 02283964 · $2.0000 Teva-Leflunomide · DIN 02261251 · $2.0000

Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02241888

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Leflunomide · DIN 02351668 · 10mg · tablet

General benefitMarketed · checked 2026-09-19

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Leflunomide · DIN 02351668 Manufacturer: Sanis Health Inc.; listing date 2011-08-04 Health Canada: Marketed since 2014-07-12 · brand LEFLUNOMIDE · ATC L04AK01 LEFLUNOMIDE · form Tablet · route Oral · ingredients LEFLUNOMIDE 10 MG · company Sanis health inc · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $2.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83692 · Verify on the e-Formulary ↗ (DIN 02351668)

Source record

DIN 02351668: Leflunomide Raw flags: sec3=Y Item: 920000369; group id 926; item number 2205; lccId None; manufacturer id SAI Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $2.6433; ministry $2.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02351668 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83692

Interchangeable products

Accel-Leflunomide · DIN 02478862 · $2.0000 Apo-Leflunomide · DIN 02256495 · $2.0000 Arava · DIN 02241888 · $2.0000 Leflunomide · DIN 02543575 · $2.0000 Mar-Leflunomide · DIN 02551918 · $2.0000 Sandoz Leflunomide · DIN 02283964 · $2.0000 Teva-Leflunomide · DIN 02261251 · $2.0000

Shortage status: resolved shortage (ended 2023-09-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02351668

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Leflunomide · DIN 02543575 · 10mg · tablet

General benefitMarketed · checked 2026-09-19

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Leflunomide · DIN 02543575 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2024-07-31 Health Canada: Marketed since 2024-06-03 · brand LEFLUNOMIDE · ATC L04AK01 LEFLUNOMIDE · form Tablet · route Oral · ingredients LEFLUNOMIDE 10 MG · company Sivem pharmaceuticals ulc · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $2.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103203 · Verify on the e-Formulary ↗ (DIN 02543575)

Source record

DIN 02543575: Leflunomide Raw flags: sec3=Y Item: 920000369; group id 926; item number 2205; lccId None; manufacturer id SIV Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $2.6433; ministry $2.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02543575 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103203

Interchangeable products

Accel-Leflunomide · DIN 02478862 · $2.0000 Apo-Leflunomide · DIN 02256495 · $2.0000 Arava · DIN 02241888 · $2.0000 Leflunomide · DIN 02351668 · $2.0000 Mar-Leflunomide · DIN 02551918 · $2.0000 Sandoz Leflunomide · DIN 02283964 · $2.0000 Teva-Leflunomide · DIN 02261251 · $2.0000

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02543575

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mar-Leflunomide · DIN 02551918 · 10mg · tablet

General benefitMarketed · checked 2026-09-19

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Mar-Leflunomide · DIN 02551918 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2025-01-31 Health Canada: Marketed since 2024-12-04 · brand MAR-LEFLUNOMIDE · ATC L04AK01 LEFLUNOMIDE · form Tablet · route Oral · ingredients LEFLUNOMIDE 10 MG · company Marcan pharmaceuticals inc · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $2.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104061 · Verify on the e-Formulary ↗ (DIN 02551918)

Source record

DIN 02551918: Mar-Leflunomide Raw flags: sec3=Y Item: 920000369; group id 926; item number 2205; lccId None; manufacturer id MAR Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $2.6433; ministry $2.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02551918 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104061

Interchangeable products

Accel-Leflunomide · DIN 02478862 · $2.0000 Apo-Leflunomide · DIN 02256495 · $2.0000 Arava · DIN 02241888 · $2.0000 Leflunomide · DIN 02351668 · $2.0000 Leflunomide · DIN 02543575 · $2.0000 Sandoz Leflunomide · DIN 02283964 · $2.0000 Teva-Leflunomide · DIN 02261251 · $2.0000

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02551918

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Leflunomide · DIN 02283964 · 10mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Sandoz Leflunomide · DIN 02283964 Manufacturer: Sandoz Canada Inc.; listing date 2007-01-02 Health Canada: Marketed since 2006-08-15 · brand SANDOZ LEFLUNOMIDE · ATC L04AK01 LEFLUNOMIDE · form Tablet · route Oral · ingredients LEFLUNOMIDE 10 MG · company Sandoz canada incorporated · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $2.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76953 · Verify on the e-Formulary ↗ (DIN 02283964)

Source record

DIN 02283964: Sandoz Leflunomide Raw flags: sec3=Y Item: 920000369; group id 926; item number 2205; lccId None; manufacturer id SDZ Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $2.6433; ministry $2.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02283964 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76953

Interchangeable products

Accel-Leflunomide · DIN 02478862 · $2.0000 Apo-Leflunomide · DIN 02256495 · $2.0000 Arava · DIN 02241888 · $2.0000 Leflunomide · DIN 02351668 · $2.0000 Leflunomide · DIN 02543575 · $2.0000 Mar-Leflunomide · DIN 02551918 · $2.0000 Teva-Leflunomide · DIN 02261251 · $2.0000

Shortage status: active shortage (reported 2026-07-13, estimated to end 2026-10-30, last updated 2026-08-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02283964

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Leflunomide · DIN 02261251 · 10mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Teva-Leflunomide · DIN 02261251 Manufacturer: Teva Canada Limited; listing date 2005-01-25 Health Canada: Marketed since 2014-02-14 · brand TEVA-LEFLUNOMIDE · ATC L04AK01 LEFLUNOMIDE · form Tablet · route Oral · ingredients LEFLUNOMIDE 10 MG · company Teva canada limited · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $2.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74665 · Verify on the e-Formulary ↗ (DIN 02261251)

Source record

DIN 02261251: Teva-Leflunomide Raw flags: sec3=Y Item: 920000369; group id 926; item number 2205; lccId None; manufacturer id TEV Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $2.6433; ministry $2.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02261251 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74665

Interchangeable products

Accel-Leflunomide · DIN 02478862 · $2.0000 Apo-Leflunomide · DIN 02256495 · $2.0000 Arava · DIN 02241888 · $2.0000 Leflunomide · DIN 02351668 · $2.0000 Leflunomide · DIN 02543575 · $2.0000 Mar-Leflunomide · DIN 02551918 · $2.0000 Sandoz Leflunomide · DIN 02283964 · $2.0000

Shortage status: resolved shortage (ended 2026-06-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02261251

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Accel-Leflunomide · DIN 02478870 · 20mg · tablet

General benefitMarketed · checked 2026-09-19

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Accel-Leflunomide · DIN 02478870 Manufacturer: Accel Pharma Inc.; listing date 2019-12-20 Health Canada: Marketed since 2019-09-19 · brand ACCEL-LEFLUNOMIDE · ATC L04AK01 LEFLUNOMIDE · form Tablet · route Oral · ingredients LEFLUNOMIDE 20 MG · company Accel pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

Accel-Leflunomide: Formulary list price $2.0000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96958 · Verify on the e-Formulary ↗ (DIN 02478870)

Source record

DIN 02478870: Accel-Leflunomide Raw flags: sec3=Y Item: 920000370; group id 926; item number 2206; lccId None; manufacturer id ACC Source form: Tab; strength: 20mg Recorded listing: General benefit Source prices (unrounded): $2.0000; ministry $2.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02478870 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96958

Interchangeable products

Apo-Leflunomide · DIN 02256509 · $2.0000 Arava · DIN 02241889 · $2.0000 Leflunomide · DIN 02351676 · $2.0000 Leflunomide · DIN 02543583 · $2.0000 Mar-Leflunomide · DIN 02551926 · $2.0000 Sandoz Leflunomide · DIN 02283972 · $2.0000 Teva-Leflunomide · DIN 02261278 · $2.0000

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02478870

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Leflunomide · DIN 02256509 · 20mg · tablet

General benefitMarketed · checked 2026-09-19

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Apo-Leflunomide · DIN 02256509 Manufacturer: Apotex Inc.; listing date 2004-11-16 Health Canada: Marketed since 2004-09-14 · brand APO-LEFLUNOMIDE · ATC L04AK01 LEFLUNOMIDE · form Tablet · route Oral · ingredients LEFLUNOMIDE 20 MG · company Apotex inc · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $2.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74174 · Verify on the e-Formulary ↗ (DIN 02256509)

Source record

DIN 02256509: Apo-Leflunomide Raw flags: sec3=Y Item: 920000370; group id 926; item number 2206; lccId None; manufacturer id APX Source form: Tab; strength: 20mg Recorded listing: General benefit Source prices (unrounded): $2.6433; ministry $2.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02256509 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74174

Interchangeable products

Accel-Leflunomide · DIN 02478870 · $2.0000 Arava · DIN 02241889 · $2.0000 Leflunomide · DIN 02351676 · $2.0000 Leflunomide · DIN 02543583 · $2.0000 Mar-Leflunomide · DIN 02551926 · $2.0000 Sandoz Leflunomide · DIN 02283972 · $2.0000 Teva-Leflunomide · DIN 02261278 · $2.0000

Shortage status: shortage reported ended 2026-08-13 (report last updated 2026-08-13); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02256509

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Arava · DIN 02241889 · 20mg · tablet

General benefitMarketed · checked 2026-09-19

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Savings card: RxHelp ONE lists Arava (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)

1 brand, same coverage

Arava · DIN 02241889 Manufacturer: Sanofi Aventis Pharma; listing date 2001-03-07 Health Canada: Marketed since 2008-10-10 · brand ARAVA · ATC L04AK01 LEFLUNOMIDE · form Tablet · route Oral · ingredients LEFLUNOMIDE 20 MG · company Sanofi-aventis canada inc · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $2.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65559 · Verify on the e-Formulary ↗ (DIN 02241889)

Source record

DIN 02241889: Arava Raw flags: sec3=Y Item: 920000370; group id 926; item number 2206; lccId None; manufacturer id SAV Source form: Tab; strength: 20mg Recorded listing: General benefit Source prices (unrounded): $11.4443; ministry $2.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02241889 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65559

Interchangeable products

Accel-Leflunomide · DIN 02478870 · $2.0000 Apo-Leflunomide · DIN 02256509 · $2.0000 Leflunomide · DIN 02351676 · $2.0000 Leflunomide · DIN 02543583 · $2.0000 Mar-Leflunomide · DIN 02551926 · $2.0000 Sandoz Leflunomide · DIN 02283972 · $2.0000 Teva-Leflunomide · DIN 02261278 · $2.0000

Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02241889

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Leflunomide · DIN 02351676 · 20mg · tablet

General benefitMarketed · checked 2026-09-19

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Leflunomide · DIN 02351676 Manufacturer: Sanis Health Inc.; listing date 2011-08-04 Health Canada: Marketed since 2014-07-12 · brand LEFLUNOMIDE · ATC L04AK01 LEFLUNOMIDE · form Tablet · route Oral · ingredients LEFLUNOMIDE 20 MG · company Sanis health inc · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $2.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83693 · Verify on the e-Formulary ↗ (DIN 02351676)

Source record

DIN 02351676: Leflunomide Raw flags: sec3=Y Item: 920000370; group id 926; item number 2206; lccId None; manufacturer id SAI Source form: Tab; strength: 20mg Recorded listing: General benefit Source prices (unrounded): $2.6433; ministry $2.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02351676 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83693

Interchangeable products

Accel-Leflunomide · DIN 02478870 · $2.0000 Apo-Leflunomide · DIN 02256509 · $2.0000 Arava · DIN 02241889 · $2.0000 Leflunomide · DIN 02543583 · $2.0000 Mar-Leflunomide · DIN 02551926 · $2.0000 Sandoz Leflunomide · DIN 02283972 · $2.0000 Teva-Leflunomide · DIN 02261278 · $2.0000

Shortage status: resolved shortage (ended 2023-11-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02351676

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Leflunomide · DIN 02543583 · 20mg · tablet

General benefitMarketed · checked 2026-09-19

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Leflunomide · DIN 02543583 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2024-07-31 Health Canada: Marketed since 2024-06-03 · brand LEFLUNOMIDE · ATC L04AK01 LEFLUNOMIDE · form Tablet · route Oral · ingredients LEFLUNOMIDE 20 MG · company Sivem pharmaceuticals ulc · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $2.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103204 · Verify on the e-Formulary ↗ (DIN 02543583)

Source record

DIN 02543583: Leflunomide Raw flags: sec3=Y Item: 920000370; group id 926; item number 2206; lccId None; manufacturer id SIV Source form: Tab; strength: 20mg Recorded listing: General benefit Source prices (unrounded): $2.6433; ministry $2.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02543583 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103204

Interchangeable products

Accel-Leflunomide · DIN 02478870 · $2.0000 Apo-Leflunomide · DIN 02256509 · $2.0000 Arava · DIN 02241889 · $2.0000 Leflunomide · DIN 02351676 · $2.0000 Mar-Leflunomide · DIN 02551926 · $2.0000 Sandoz Leflunomide · DIN 02283972 · $2.0000 Teva-Leflunomide · DIN 02261278 · $2.0000

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02543583

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mar-Leflunomide · DIN 02551926 · 20mg · tablet

General benefitMarketed · checked 2026-09-19

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Mar-Leflunomide · DIN 02551926 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2025-01-31 Health Canada: Marketed since 2024-12-04 · brand MAR-LEFLUNOMIDE · ATC L04AK01 LEFLUNOMIDE · form Tablet · route Oral · ingredients LEFLUNOMIDE 20 MG · company Marcan pharmaceuticals inc · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $2.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104062 · Verify on the e-Formulary ↗ (DIN 02551926)

Source record

DIN 02551926: Mar-Leflunomide Raw flags: sec3=Y Item: 920000370; group id 926; item number 2206; lccId None; manufacturer id MAR Source form: Tab; strength: 20mg Recorded listing: General benefit Source prices (unrounded): $2.6433; ministry $2.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02551926 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104062

Interchangeable products

Accel-Leflunomide · DIN 02478870 · $2.0000 Apo-Leflunomide · DIN 02256509 · $2.0000 Arava · DIN 02241889 · $2.0000 Leflunomide · DIN 02351676 · $2.0000 Leflunomide · DIN 02543583 · $2.0000 Sandoz Leflunomide · DIN 02283972 · $2.0000 Teva-Leflunomide · DIN 02261278 · $2.0000

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02551926

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Leflunomide · DIN 02283972 · 20mg · tablet

General benefitMarketed · checked 2026-09-19

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Sandoz Leflunomide · DIN 02283972 Manufacturer: Sandoz Canada Inc.; listing date 2007-01-02 Health Canada: Marketed since 2006-08-15 · brand SANDOZ LEFLUNOMIDE · ATC L04AK01 LEFLUNOMIDE · form Tablet · route Oral · ingredients LEFLUNOMIDE 20 MG · company Sandoz canada incorporated · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $2.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76954 · Verify on the e-Formulary ↗ (DIN 02283972)

Source record

DIN 02283972: Sandoz Leflunomide Raw flags: sec3=Y Item: 920000370; group id 926; item number 2206; lccId None; manufacturer id SDZ Source form: Tab; strength: 20mg Recorded listing: General benefit Source prices (unrounded): $2.6433; ministry $2.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02283972 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76954

Interchangeable products

Accel-Leflunomide · DIN 02478870 · $2.0000 Apo-Leflunomide · DIN 02256509 · $2.0000 Arava · DIN 02241889 · $2.0000 Leflunomide · DIN 02351676 · $2.0000 Leflunomide · DIN 02543583 · $2.0000 Mar-Leflunomide · DIN 02551926 · $2.0000 Teva-Leflunomide · DIN 02261278 · $2.0000

Shortage status: resolved shortage (ended 2026-08-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02283972

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Leflunomide · DIN 02261278 · 20mg · tablet

General benefitMarketed · checked 2026-09-19

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Teva-Leflunomide · DIN 02261278 Manufacturer: Teva Canada Limited; listing date 2005-01-25 Health Canada: Marketed since 2014-02-14 · brand TEVA-LEFLUNOMIDE · ATC L04AK01 LEFLUNOMIDE · form Tablet · route Oral · ingredients LEFLUNOMIDE 20 MG · company Teva canada limited · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $2.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74666 · Verify on the e-Formulary ↗ (DIN 02261278)

Source record

DIN 02261278: Teva-Leflunomide Raw flags: sec3=Y Item: 920000370; group id 926; item number 2206; lccId None; manufacturer id TEV Source form: Tab; strength: 20mg Recorded listing: General benefit Source prices (unrounded): $2.6433; ministry $2.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02261278 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74666

Interchangeable products

Accel-Leflunomide · DIN 02478870 · $2.0000 Apo-Leflunomide · DIN 02256509 · $2.0000 Arava · DIN 02241889 · $2.0000 Leflunomide · DIN 02351676 · $2.0000 Leflunomide · DIN 02543583 · $2.0000 Mar-Leflunomide · DIN 02551926 · $2.0000 Sandoz Leflunomide · DIN 02283972 · $2.0000

Shortage status: resolved shortage (ended 2026-03-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02261278

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Look up one drug

LEFLUNOMIDE

Accel-Leflunomide · DIN 02478862 · 10mg · tablet

Apo-Leflunomide · DIN 02256495 · 10mg · tablet

Arava · DIN 02241888 · 10mg · tablet

Leflunomide · DIN 02351668 · 10mg · tablet

Leflunomide · DIN 02543575 · 10mg · tablet

Mar-Leflunomide · DIN 02551918 · 10mg · tablet

Sandoz Leflunomide · DIN 02283964 · 10mg · tablet

Teva-Leflunomide · DIN 02261251 · 10mg · tablet

Accel-Leflunomide · DIN 02478870 · 20mg · tablet

Apo-Leflunomide · DIN 02256509 · 20mg · tablet

Arava · DIN 02241889 · 20mg · tablet

Leflunomide · DIN 02351676 · 20mg · tablet

Leflunomide · DIN 02543583 · 20mg · tablet

Mar-Leflunomide · DIN 02551926 · 20mg · tablet

Sandoz Leflunomide · DIN 02283972 · 20mg · tablet

Teva-Leflunomide · DIN 02261278 · 20mg · tablet

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

TERIFLUNOMIDE

AZATHIOPRINE

CYCLOSPORINE

MYCOPHENOLATE MOFETIL

MYCOPHENOLATE SODIUM

LENALIDOMIDE

SIROLIMUS

TACROLIMUS

USTEKINUMAB

FINGOLIMOD

PIRFENIDONE

ALENDRONATE

Availability